 BLACKSBURG, Va., May 19, 2021 GLOBE NEWSWIRE -- Landos Biopharma, Inc NASDAQ: LABP, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced the appointment of Tim M. Mayleben to its Board of Directors. Mr. Mayleben joins Landos with more than 20 years of executive experience leading development activities as well as successfully spearheading clinical and business strategies within the life sciences industry. 